Sector News

Analysts: Avanir could have scored higher bids–but now, its hands may be tied

December 4, 2014
Life sciences
Avanir, which agreed to sell itself to Otsuka earlier this week for $3.5 billion, may have been able to snag another price, some analysts figure. Problem is, it may too late to do anything about it.
 
As Jefferies Group’s Thomas Wei sees it, Avanir could have scored $26 to $31 per share in a takeover, rather than the $17 a share it decided on with Otsuka. And that could have meant an additional $1.7 billion for Avanir shareholders, Bloomberg reports.
 
Cowen Group analyst Ritu Baral agreed, calling Otsuka’s bid “underwhelming” in a note seen by the news service.
 
While counterbidders could still swoop in, Avanir has inked a pact not to seek them out, Bloomberg notes. And if it opts out of the Otsuka agreement, it’ll be forced to fork over $90 million to the Japanese drugmaker.
 
So shareholders will have to hope for an unsolicited higher bid if they want something more to line their pockets. And while Baral said she sees “no evidence” of other potential bidders at this point, she thinks there could have been some out there.
 
Take Teva, which has made recent investments in CNS products, or Actavis, which bought Forest Labs earlier this year to pick up Alzheimer’s treatment Namenda. Either could be interested in gaining access to Avanir’s Neudexta, the only approved treatment for the neurologic disease pseudobulbar affect. The company is currently testing the fast-growing drug, which won’t see generic competition for at least 12 years, to treat agitation in Alzheimer’s patients–a much larger market, Bloomberg notes.
 
Lundbeck, Mallinckrodt and Shire could also make logical buyers, JMP Group analyst Jason Butler told the news service in October. Lundbeck and Mallinckrodt both boast brain-disease treatments, while ADHD expert Shire–seeking deals of its own after the collapse of a merger with Illinois’ AbbVie–could add to its growing rare-disease lineup.
 
Indeed, another interested buyer approached Avanir back in September, an unnamed source told Bloomberg. But that company dropped out of the running when positive Phase II data for another version of Neudexta sent shares soaring, triggering an 85% one-day leap that put the deal out of range for Avanir’s suitor, the source said.
 
By Carly Helfand
 

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend